nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—GLI1—pancreatic cancer	0.00693	0.061	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—SHH—pancreatic cancer	0.00501	0.0441	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—GLI1—pancreatic cancer	0.00413	0.0364	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—FGF13—pancreatic cancer	0.00378	0.0333	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—FGF13—pancreatic cancer	0.00335	0.0295	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—SHH—pancreatic cancer	0.00299	0.0263	CbGpPWpGaD
Lisdexamfetamine—Urticaria—Tamoxifen—pancreatic cancer	0.00264	0.00297	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Erlotinib—pancreatic cancer	0.0026	0.00293	CcSEcCtD
Lisdexamfetamine—Weight increased—Docetaxel—pancreatic cancer	0.00259	0.00292	CcSEcCtD
Lisdexamfetamine—Vision blurred—Fluorouracil—pancreatic cancer	0.00259	0.00292	CcSEcCtD
Lisdexamfetamine—Weight decreased—Docetaxel—pancreatic cancer	0.00258	0.00291	CcSEcCtD
Lisdexamfetamine—Insomnia—Sunitinib—pancreatic cancer	0.00257	0.0029	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Sunitinib—pancreatic cancer	0.00253	0.00286	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.00252	0.00284	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Sunitinib—pancreatic cancer	0.0025	0.00282	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.0025	0.00282	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Docetaxel—pancreatic cancer	0.00249	0.00281	CcSEcCtD
Lisdexamfetamine—Hypertension—Irinotecan—pancreatic cancer	0.00248	0.00279	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Sunitinib—pancreatic cancer	0.00247	0.00279	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00245	0.00277	CcSEcCtD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.00245	0.0216	CbGpPWpGaD
Lisdexamfetamine—Fatigue—Sunitinib—pancreatic cancer	0.00245	0.00276	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00245	0.00276	CcSEcCtD
Lisdexamfetamine—Constipation—Sunitinib—pancreatic cancer	0.00243	0.00274	CcSEcCtD
Lisdexamfetamine—Hypertension—Gemcitabine—pancreatic cancer	0.00241	0.00272	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.0024	0.00271	CcSEcCtD
Lisdexamfetamine—Asthenia—Tamoxifen—pancreatic cancer	0.00238	0.00269	CcSEcCtD
Lisdexamfetamine—Convulsion—Fluorouracil—pancreatic cancer	0.00238	0.00269	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00236	0.00267	CcSEcCtD
Lisdexamfetamine—Asthenia—Erlotinib—pancreatic cancer	0.00236	0.00266	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00234	0.00264	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Irinotecan—pancreatic cancer	0.0023	0.00259	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00228	0.00257	CcSEcCtD
Lisdexamfetamine—Hepatitis—Docetaxel—pancreatic cancer	0.00228	0.00257	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Tamoxifen—pancreatic cancer	0.00227	0.00256	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Epirubicin—pancreatic cancer	0.00227	0.00256	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Irinotecan—pancreatic cancer	0.00226	0.00255	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Sunitinib—pancreatic cancer	0.00225	0.00253	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Erlotinib—pancreatic cancer	0.00225	0.00253	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00224	0.00253	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00224	0.00252	CcSEcCtD
Lisdexamfetamine—Anorexia—Irinotecan—pancreatic cancer	0.00223	0.00252	CcSEcCtD
Lisdexamfetamine—Diplopia—Epirubicin—pancreatic cancer	0.00222	0.00251	CcSEcCtD
Lisdexamfetamine—Skin disorder—Gemcitabine—pancreatic cancer	0.00222	0.0025	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.00221	0.00249	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.0022	0.00248	CcSEcCtD
Lisdexamfetamine—Visual impairment—Docetaxel—pancreatic cancer	0.0022	0.00248	CcSEcCtD
Lisdexamfetamine—Dizziness—Tamoxifen—pancreatic cancer	0.00219	0.00248	CcSEcCtD
Lisdexamfetamine—Tachycardia—Fluorouracil—pancreatic cancer	0.00219	0.00247	CcSEcCtD
Lisdexamfetamine—Affect lability—Epirubicin—pancreatic cancer	0.00219	0.00247	CcSEcCtD
Lisdexamfetamine—Anorexia—Gemcitabine—pancreatic cancer	0.00217	0.00245	CcSEcCtD
Lisdexamfetamine—Dizziness—Erlotinib—pancreatic cancer	0.00217	0.00245	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Docetaxel—pancreatic cancer	0.00215	0.00243	CcSEcCtD
Lisdexamfetamine—Anorexia—Fluorouracil—pancreatic cancer	0.00214	0.00241	CcSEcCtD
Lisdexamfetamine—Eye disorder—Docetaxel—pancreatic cancer	0.00213	0.0024	CcSEcCtD
Lisdexamfetamine—Insomnia—Irinotecan—pancreatic cancer	0.00212	0.00239	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Docetaxel—pancreatic cancer	0.00211	0.00239	CcSEcCtD
Lisdexamfetamine—Vomiting—Tamoxifen—pancreatic cancer	0.00211	0.00238	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.0021	0.00237	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Sunitinib—pancreatic cancer	0.00209	0.00236	CcSEcCtD
Lisdexamfetamine—Rash—Tamoxifen—pancreatic cancer	0.00209	0.00236	CcSEcCtD
Lisdexamfetamine—Dermatitis—Tamoxifen—pancreatic cancer	0.00209	0.00236	CcSEcCtD
Lisdexamfetamine—Vomiting—Erlotinib—pancreatic cancer	0.00209	0.00236	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Irinotecan—pancreatic cancer	0.00209	0.00235	CcSEcCtD
Lisdexamfetamine—Somnolence—Irinotecan—pancreatic cancer	0.00208	0.00235	CcSEcCtD
Lisdexamfetamine—Headache—Tamoxifen—pancreatic cancer	0.00208	0.00235	CcSEcCtD
Lisdexamfetamine—Rash—Erlotinib—pancreatic cancer	0.00207	0.00234	CcSEcCtD
Lisdexamfetamine—Dermatitis—Erlotinib—pancreatic cancer	0.00207	0.00233	CcSEcCtD
Lisdexamfetamine—Insomnia—Gemcitabine—pancreatic cancer	0.00206	0.00233	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Irinotecan—pancreatic cancer	0.00206	0.00233	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Docetaxel—pancreatic cancer	0.00206	0.00232	CcSEcCtD
Lisdexamfetamine—Headache—Erlotinib—pancreatic cancer	0.00206	0.00232	CcSEcCtD
Lisdexamfetamine—Diplopia—Doxorubicin—pancreatic cancer	0.00206	0.00232	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Docetaxel—pancreatic cancer	0.00205	0.00232	CcSEcCtD
Lisdexamfetamine—Asthenia—Sunitinib—pancreatic cancer	0.00204	0.0023	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—pancreatic cancer	0.00204	0.018	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Irinotecan—pancreatic cancer	0.00204	0.0023	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Gemcitabine—pancreatic cancer	0.00203	0.00229	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Epirubicin—pancreatic cancer	0.00203	0.00229	CcSEcCtD
Lisdexamfetamine—Insomnia—Fluorouracil—pancreatic cancer	0.00203	0.00229	CcSEcCtD
Lisdexamfetamine—Somnolence—Gemcitabine—pancreatic cancer	0.00203	0.00229	CcSEcCtD
Lisdexamfetamine—Affect lability—Doxorubicin—pancreatic cancer	0.00202	0.00228	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00202	0.00228	CcSEcCtD
Lisdexamfetamine—Fatigue—Irinotecan—pancreatic cancer	0.00202	0.00228	CcSEcCtD
Lisdexamfetamine—Constipation—Irinotecan—pancreatic cancer	0.002	0.00226	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.002	0.00226	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Fluorouracil—pancreatic cancer	0.002	0.00226	CcSEcCtD
Lisdexamfetamine—Mental disorder—Docetaxel—pancreatic cancer	0.002	0.00225	CcSEcCtD
Lisdexamfetamine—Somnolence—Fluorouracil—pancreatic cancer	0.00199	0.00225	CcSEcCtD
Lisdexamfetamine—Malnutrition—Docetaxel—pancreatic cancer	0.00198	0.00224	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Gemcitabine—pancreatic cancer	0.00198	0.00224	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Fluorouracil—pancreatic cancer	0.00197	0.00223	CcSEcCtD
Lisdexamfetamine—Nausea—Tamoxifen—pancreatic cancer	0.00197	0.00222	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00197	0.00222	CcSEcCtD
Lisdexamfetamine—Fatigue—Gemcitabine—pancreatic cancer	0.00197	0.00222	CcSEcCtD
Lisdexamfetamine—Constipation—Gemcitabine—pancreatic cancer	0.00195	0.0022	CcSEcCtD
Lisdexamfetamine—Nausea—Erlotinib—pancreatic cancer	0.00195	0.0022	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Fluorouracil—pancreatic cancer	0.00195	0.0022	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Sunitinib—pancreatic cancer	0.00194	0.00219	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00194	0.00218	CcSEcCtD
Lisdexamfetamine—Dizziness—Sunitinib—pancreatic cancer	0.00188	0.00212	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.00188	0.00212	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Irinotecan—pancreatic cancer	0.00185	0.00209	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.00185	0.00209	CcSEcCtD
Lisdexamfetamine—Vomiting—Sunitinib—pancreatic cancer	0.00181	0.00204	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Gemcitabine—pancreatic cancer	0.0018	0.00203	CcSEcCtD
Lisdexamfetamine—Rash—Sunitinib—pancreatic cancer	0.00179	0.00202	CcSEcCtD
Lisdexamfetamine—Dermatitis—Sunitinib—pancreatic cancer	0.00179	0.00202	CcSEcCtD
Lisdexamfetamine—Urticaria—Fluorouracil—pancreatic cancer	0.00178	0.00201	CcSEcCtD
Lisdexamfetamine—Headache—Sunitinib—pancreatic cancer	0.00178	0.00201	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Fluorouracil—pancreatic cancer	0.00177	0.002	CcSEcCtD
Lisdexamfetamine—Palpitations—Docetaxel—pancreatic cancer	0.00175	0.00198	CcSEcCtD
Lisdexamfetamine—Weight increased—Epirubicin—pancreatic cancer	0.00175	0.00197	CcSEcCtD
Lisdexamfetamine—Weight decreased—Epirubicin—pancreatic cancer	0.00174	0.00196	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Irinotecan—pancreatic cancer	0.00173	0.00195	CcSEcCtD
Lisdexamfetamine—Convulsion—Docetaxel—pancreatic cancer	0.00172	0.00194	CcSEcCtD
Lisdexamfetamine—Hypertension—Docetaxel—pancreatic cancer	0.00171	0.00193	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.0017	0.00191	CcSEcCtD
Lisdexamfetamine—Nausea—Sunitinib—pancreatic cancer	0.00169	0.0019	CcSEcCtD
Lisdexamfetamine—Asthenia—Irinotecan—pancreatic cancer	0.00168	0.0019	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.00168	0.00189	CcSEcCtD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TSC2—pancreatic cancer	0.00166	0.0146	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00165	0.00186	CcSEcCtD
Lisdexamfetamine—Dry mouth—Docetaxel—pancreatic cancer	0.00165	0.00186	CcSEcCtD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.00165	0.0145	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Gemcitabine—pancreatic cancer	0.00164	0.00185	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.00162	0.00183	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.00162	0.00183	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—pancreatic cancer	0.00162	0.00182	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—pancreatic cancer	0.00161	0.00181	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Irinotecan—pancreatic cancer	0.0016	0.00181	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Docetaxel—pancreatic cancer	0.00159	0.00179	CcSEcCtD
Lisdexamfetamine—Tachycardia—Docetaxel—pancreatic cancer	0.00158	0.00178	CcSEcCtD
Lisdexamfetamine—Skin disorder—Docetaxel—pancreatic cancer	0.00157	0.00177	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.00157	0.00177	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Gemcitabine—pancreatic cancer	0.00156	0.00176	CcSEcCtD
Lisdexamfetamine—Dizziness—Irinotecan—pancreatic cancer	0.00155	0.00175	CcSEcCtD
Lisdexamfetamine—Anorexia—Docetaxel—pancreatic cancer	0.00154	0.00174	CcSEcCtD
Lisdexamfetamine—Hepatitis—Epirubicin—pancreatic cancer	0.00154	0.00173	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Fluorouracil—pancreatic cancer	0.00153	0.00173	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.00153	0.0135	CbGpPWpGaD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.0015	0.00169	CcSEcCtD
Lisdexamfetamine—Vomiting—Irinotecan—pancreatic cancer	0.00149	0.00168	CcSEcCtD
Lisdexamfetamine—Dizziness—Fluorouracil—pancreatic cancer	0.00148	0.00167	CcSEcCtD
Lisdexamfetamine—Visual impairment—Epirubicin—pancreatic cancer	0.00148	0.00167	CcSEcCtD
Lisdexamfetamine—Rash—Irinotecan—pancreatic cancer	0.00148	0.00167	CcSEcCtD
Lisdexamfetamine—Dermatitis—Irinotecan—pancreatic cancer	0.00148	0.00166	CcSEcCtD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TSC2—pancreatic cancer	0.00147	0.013	CbGpPWpGaD
Lisdexamfetamine—Headache—Irinotecan—pancreatic cancer	0.00147	0.00165	CcSEcCtD
Lisdexamfetamine—Insomnia—Docetaxel—pancreatic cancer	0.00146	0.00165	CcSEcCtD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.00146	0.0129	CbGpPWpGaD
Lisdexamfetamine—Erythema multiforme—Epirubicin—pancreatic cancer	0.00145	0.00164	CcSEcCtD
Lisdexamfetamine—Vomiting—Gemcitabine—pancreatic cancer	0.00145	0.00164	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Docetaxel—pancreatic cancer	0.00144	0.00163	CcSEcCtD
Lisdexamfetamine—Somnolence—Docetaxel—pancreatic cancer	0.00144	0.00162	CcSEcCtD
Lisdexamfetamine—Rash—Gemcitabine—pancreatic cancer	0.00144	0.00162	CcSEcCtD
Lisdexamfetamine—Dermatitis—Gemcitabine—pancreatic cancer	0.00144	0.00162	CcSEcCtD
Lisdexamfetamine—Eye disorder—Epirubicin—pancreatic cancer	0.00144	0.00162	CcSEcCtD
Lisdexamfetamine—Headache—Gemcitabine—pancreatic cancer	0.00143	0.00161	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Epirubicin—pancreatic cancer	0.00143	0.00161	CcSEcCtD
Lisdexamfetamine—Vomiting—Fluorouracil—pancreatic cancer	0.00143	0.00161	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Docetaxel—pancreatic cancer	0.00142	0.00161	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—pancreatic cancer	0.00142	0.0016	CcSEcCtD
Lisdexamfetamine—Rash—Fluorouracil—pancreatic cancer	0.00141	0.0016	CcSEcCtD
Lisdexamfetamine—Dermatitis—Fluorouracil—pancreatic cancer	0.00141	0.00159	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Docetaxel—pancreatic cancer	0.00141	0.00159	CcSEcCtD
Lisdexamfetamine—Headache—Fluorouracil—pancreatic cancer	0.0014	0.00158	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.0014	0.00158	CcSEcCtD
Lisdexamfetamine—Fatigue—Docetaxel—pancreatic cancer	0.0014	0.00157	CcSEcCtD
Lisdexamfetamine—Nausea—Irinotecan—pancreatic cancer	0.00139	0.00157	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Epirubicin—pancreatic cancer	0.00139	0.00157	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Epirubicin—pancreatic cancer	0.00138	0.00156	CcSEcCtD
Lisdexamfetamine—Constipation—Docetaxel—pancreatic cancer	0.00138	0.00156	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—pancreatic cancer	0.00137	0.0121	CbGpPWpGaD
Lisdexamfetamine—Visual impairment—Doxorubicin—pancreatic cancer	0.00137	0.00155	CcSEcCtD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—pancreatic cancer	0.00136	0.012	CbGpPWpGaD
Lisdexamfetamine—Nausea—Gemcitabine—pancreatic cancer	0.00135	0.00153	CcSEcCtD
Lisdexamfetamine—Mental disorder—Epirubicin—pancreatic cancer	0.00135	0.00152	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—pancreatic cancer	0.00134	0.00152	CcSEcCtD
Lisdexamfetamine—Malnutrition—Epirubicin—pancreatic cancer	0.00134	0.00151	CcSEcCtD
Lisdexamfetamine—Nausea—Fluorouracil—pancreatic cancer	0.00133	0.0015	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—pancreatic cancer	0.00133	0.0015	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—pancreatic cancer	0.00132	0.00149	CcSEcCtD
Lisdexamfetamine—Nervousness—Epirubicin—pancreatic cancer	0.0013	0.00147	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—pancreatic cancer	0.00128	0.00145	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.00128	0.00145	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Docetaxel—pancreatic cancer	0.00128	0.00144	CcSEcCtD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—TGFB1—pancreatic cancer	0.00126	0.0111	CbGpPWpGaD
Lisdexamfetamine—Vision blurred—Epirubicin—pancreatic cancer	0.00126	0.00142	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.00125	0.011	CbGpPWpGaD
Lisdexamfetamine—Mental disorder—Doxorubicin—pancreatic cancer	0.00125	0.00141	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—pancreatic cancer	0.00124	0.0014	CcSEcCtD
Lisdexamfetamine—Agitation—Epirubicin—pancreatic cancer	0.00123	0.00139	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—pancreatic cancer	0.00122	0.0107	CbGpPWpGaD
Lisdexamfetamine—Nervousness—Doxorubicin—pancreatic cancer	0.0012	0.00136	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Docetaxel—pancreatic cancer	0.00119	0.00135	CcSEcCtD
Lisdexamfetamine—Palpitations—Epirubicin—pancreatic cancer	0.00118	0.00133	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—pancreatic cancer	0.00117	0.00132	CcSEcCtD
Lisdexamfetamine—Asthenia—Docetaxel—pancreatic cancer	0.00116	0.00131	CcSEcCtD
Lisdexamfetamine—Convulsion—Epirubicin—pancreatic cancer	0.00116	0.00131	CcSEcCtD
Lisdexamfetamine—Hypertension—Epirubicin—pancreatic cancer	0.00115	0.0013	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—pancreatic cancer	0.00114	0.00128	CcSEcCtD
Lisdexamfetamine—Anxiety—Epirubicin—pancreatic cancer	0.00113	0.00128	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00113	0.00128	CcSEcCtD
Lisdexamfetamine—Dry mouth—Epirubicin—pancreatic cancer	0.00111	0.00126	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Docetaxel—pancreatic cancer	0.00111	0.00125	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—pancreatic cancer	0.00109	0.00123	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Epirubicin—pancreatic cancer	0.00109	0.00123	CcSEcCtD
Lisdexamfetamine—Convulsion—Doxorubicin—pancreatic cancer	0.00107	0.00121	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Epirubicin—pancreatic cancer	0.00107	0.00121	CcSEcCtD
Lisdexamfetamine—Dizziness—Docetaxel—pancreatic cancer	0.00107	0.00121	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—pancreatic cancer	0.00107	0.00121	CcSEcCtD
Lisdexamfetamine—Tachycardia—Epirubicin—pancreatic cancer	0.00107	0.0012	CcSEcCtD
Lisdexamfetamine—Skin disorder—Epirubicin—pancreatic cancer	0.00106	0.0012	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—NFE2L2—pancreatic cancer	0.00106	0.00934	CbGpPWpGaD
Lisdexamfetamine—Hyperhidrosis—Epirubicin—pancreatic cancer	0.00106	0.00119	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—pancreatic cancer	0.00105	0.00118	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.00105	0.00118	CcSEcCtD
Lisdexamfetamine—Anorexia—Epirubicin—pancreatic cancer	0.00104	0.00117	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—pancreatic cancer	0.00103	0.00116	CcSEcCtD
Lisdexamfetamine—Vomiting—Docetaxel—pancreatic cancer	0.00103	0.00116	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.00103	0.00906	CbGpPWpGaD
Lisdexamfetamine—Rash—Docetaxel—pancreatic cancer	0.00102	0.00115	CcSEcCtD
Lisdexamfetamine—Dermatitis—Docetaxel—pancreatic cancer	0.00102	0.00115	CcSEcCtD
Lisdexamfetamine—Headache—Docetaxel—pancreatic cancer	0.00101	0.00114	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFA—pancreatic cancer	0.00101	0.00891	CbGpPWpGaD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.00101	0.00114	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000991	0.00112	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC2A2—pancreatic cancer	0.000989	0.00872	CbGpPWpGaD
Lisdexamfetamine—Insomnia—Epirubicin—pancreatic cancer	0.000987	0.00111	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—pancreatic cancer	0.000986	0.00111	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—pancreatic cancer	0.000981	0.00111	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000977	0.0011	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Epirubicin—pancreatic cancer	0.000973	0.0011	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—STK11—pancreatic cancer	0.000971	0.00855	CbGpPWpGaD
Lisdexamfetamine—Somnolence—Epirubicin—pancreatic cancer	0.000971	0.00109	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—pancreatic cancer	0.000963	0.00109	CcSEcCtD
Lisdexamfetamine—Nausea—Docetaxel—pancreatic cancer	0.000961	0.00108	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Epirubicin—pancreatic cancer	0.000961	0.00108	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Epirubicin—pancreatic cancer	0.000949	0.00107	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000943	0.00106	CcSEcCtD
Lisdexamfetamine—Fatigue—Epirubicin—pancreatic cancer	0.000941	0.00106	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—NFE2L2—pancreatic cancer	0.000939	0.00827	CbGpPWpGaD
Lisdexamfetamine—Constipation—Epirubicin—pancreatic cancer	0.000934	0.00105	CcSEcCtD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000927	0.00816	CbGpPWpGaD
Lisdexamfetamine—Insomnia—Doxorubicin—pancreatic cancer	0.000914	0.00103	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000912	0.00803	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—PRLHR—pancreatic cancer	0.000903	0.00795	CbGpPWpGaD
Lisdexamfetamine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000901	0.00102	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—pancreatic cancer	0.000898	0.00101	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFA—pancreatic cancer	0.000896	0.00789	CbGpPWpGaD
Lisdexamfetamine—Dyspepsia—Doxorubicin—pancreatic cancer	0.000889	0.001	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—CCKBR—pancreatic cancer	0.000885	0.0078	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Doxorubicin—pancreatic cancer	0.000878	0.000991	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC2A2—pancreatic cancer	0.000877	0.00772	CbGpPWpGaD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000872	0.000984	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—pancreatic cancer	0.000871	0.000982	CcSEcCtD
Lisdexamfetamine—Urticaria—Epirubicin—pancreatic cancer	0.000867	0.000978	CcSEcCtD
Lisdexamfetamine—Constipation—Doxorubicin—pancreatic cancer	0.000864	0.000975	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Epirubicin—pancreatic cancer	0.000863	0.000974	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000839	0.00739	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Alpha-synuclein signaling—SRC—pancreatic cancer	0.000819	0.00722	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—pancreatic cancer	0.000811	0.00715	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000804	0.000907	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—pancreatic cancer	0.000803	0.000905	CcSEcCtD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—pancreatic cancer	0.000799	0.00704	CbGpPWpGaD
Lisdexamfetamine—Body temperature increased—Doxorubicin—pancreatic cancer	0.000799	0.000901	CcSEcCtD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CCKBR—pancreatic cancer	0.000792	0.00697	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Epirubicin—pancreatic cancer	0.000783	0.000884	CcSEcCtD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.000774	0.00681	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—SSTR3—pancreatic cancer	0.000768	0.00676	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—GAST—pancreatic cancer	0.000761	0.00671	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—HSPA1A—pancreatic cancer	0.000761	0.0067	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TNF—pancreatic cancer	0.000753	0.00663	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—pancreatic cancer	0.000752	0.00662	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Epirubicin—pancreatic cancer	0.000747	0.000843	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000744	0.00084	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000743	0.00655	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—SSTR1—pancreatic cancer	0.000736	0.00648	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Doxorubicin—pancreatic cancer	0.000725	0.000818	CcSEcCtD
Lisdexamfetamine—Dizziness—Epirubicin—pancreatic cancer	0.000722	0.000814	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—SSTR2—pancreatic cancer	0.000709	0.00624	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Epirubicin—pancreatic cancer	0.000694	0.000783	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TSC2—pancreatic cancer	0.000694	0.00611	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Doxorubicin—pancreatic cancer	0.000691	0.00078	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—CCK—pancreatic cancer	0.000688	0.00606	CbGpPWpGaD
Lisdexamfetamine—Rash—Epirubicin—pancreatic cancer	0.000688	0.000777	CcSEcCtD
Lisdexamfetamine—Dermatitis—Epirubicin—pancreatic cancer	0.000688	0.000776	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCKBR—pancreatic cancer	0.000684	0.00603	CbGpPWpGaD
Lisdexamfetamine—Headache—Epirubicin—pancreatic cancer	0.000684	0.000772	CcSEcCtD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—pancreatic cancer	0.000681	0.006	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—HSPA1A—pancreatic cancer	0.000674	0.00594	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—NFKBIA—pancreatic cancer	0.000672	0.00592	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Doxorubicin—pancreatic cancer	0.000668	0.000754	CcSEcCtD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TNF—pancreatic cancer	0.000667	0.00587	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—CCKAR—pancreatic cancer	0.00066	0.00581	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.000658	0.00579	CbGpPWpGaD
Lisdexamfetamine—Nausea—Epirubicin—pancreatic cancer	0.000649	0.000732	CcSEcCtD
Lisdexamfetamine—Vomiting—Doxorubicin—pancreatic cancer	0.000642	0.000725	CcSEcCtD
Lisdexamfetamine—Rash—Doxorubicin—pancreatic cancer	0.000637	0.000719	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—pancreatic cancer	0.000636	0.000718	CcSEcCtD
Lisdexamfetamine—Headache—Doxorubicin—pancreatic cancer	0.000633	0.000714	CcSEcCtD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.000631	0.00556	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000624	0.00549	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.000618	0.00545	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CCK—pancreatic cancer	0.000616	0.00542	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CG—pancreatic cancer	0.000613	0.0054	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.000607	0.00535	CbGpPWpGaD
Lisdexamfetamine—Nausea—Doxorubicin—pancreatic cancer	0.0006	0.000677	CcSEcCtD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—pancreatic cancer	0.00059	0.0052	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PRLHR—pancreatic cancer	0.000589	0.00519	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.000586	0.00516	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP2—pancreatic cancer	0.000577	0.00508	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000552	0.00487	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CD—pancreatic cancer	0.000539	0.00475	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CNR2—pancreatic cancer	0.000519	0.00457	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCKAR—pancreatic cancer	0.00051	0.00449	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SSTR3—pancreatic cancer	0.000501	0.00441	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—PIK3CB—pancreatic cancer	0.000499	0.00439	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SSTR1—pancreatic cancer	0.00048	0.00423	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CXCL8—pancreatic cancer	0.000479	0.00422	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PPY—pancreatic cancer	0.000471	0.00415	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000471	0.00415	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CB—pancreatic cancer	0.00047	0.00414	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—GCG—pancreatic cancer	0.000465	0.0041	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SSTR2—pancreatic cancer	0.000462	0.00407	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CASP3—pancreatic cancer	0.000459	0.00404	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.000456	0.00402	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCKBR—pancreatic cancer	0.000446	0.00393	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.000444	0.00391	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—AGTR1—pancreatic cancer	0.000444	0.00391	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.000437	0.00385	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP9—pancreatic cancer	0.000434	0.00382	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—pancreatic cancer	0.000416	0.00366	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—SRC—pancreatic cancer	0.0004	0.00352	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—pancreatic cancer	0.000397	0.0035	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CNR1—pancreatic cancer	0.000372	0.00328	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SCT—pancreatic cancer	0.000364	0.00321	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—EGFR—pancreatic cancer	0.00035	0.00309	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCK—pancreatic cancer	0.000347	0.00306	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.000346	0.00304	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—AGTR1—pancreatic cancer	0.000343	0.00302	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CNR2—pancreatic cancer	0.000338	0.00298	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GLP1R—pancreatic cancer	0.000338	0.00298	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCKAR—pancreatic cancer	0.000333	0.00293	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.000319	0.00281	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000317	0.00279	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SHH—pancreatic cancer	0.000303	0.00267	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRLHR—pancreatic cancer	0.000302	0.00266	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—IAPP—pancreatic cancer	0.0003	0.00264	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.000294	0.00259	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PTHLH—pancreatic cancer	0.000288	0.00253	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PTCH1—pancreatic cancer	0.000288	0.00253	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CA—pancreatic cancer	0.000286	0.00252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SSTR3—pancreatic cancer	0.000283	0.00249	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—HRAS—pancreatic cancer	0.000281	0.00248	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000281	0.00247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GDI2—pancreatic cancer	0.000277	0.00244	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GDI1—pancreatic cancer	0.000277	0.00244	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—pancreatic cancer	0.000277	0.00244	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SSTR1—pancreatic cancer	0.000271	0.00239	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—pancreatic cancer	0.000268	0.00236	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PPY—pancreatic cancer	0.000266	0.00234	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SST—pancreatic cancer	0.000263	0.00232	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SSTR2—pancreatic cancer	0.000261	0.0023	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SSTR3—pancreatic cancer	0.000257	0.00226	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCKBR—pancreatic cancer	0.000252	0.00222	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—pancreatic cancer	0.000248	0.00219	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SSTR1—pancreatic cancer	0.000246	0.00217	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CNR1—pancreatic cancer	0.000243	0.00214	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PPY—pancreatic cancer	0.000242	0.00213	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB1—pancreatic cancer	0.000239	0.00211	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SSTR2—pancreatic cancer	0.000237	0.00209	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GCG—pancreatic cancer	0.000235	0.00207	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—pancreatic cancer	0.000234	0.00206	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCKBR—pancreatic cancer	0.000229	0.00202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AGTR1—pancreatic cancer	0.000224	0.00197	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—pancreatic cancer	0.000218	0.00192	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GAST—pancreatic cancer	0.000217	0.00191	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB1—pancreatic cancer	0.000212	0.00187	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SCT—pancreatic cancer	0.000206	0.00181	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GAST—pancreatic cancer	0.000197	0.00174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCK—pancreatic cancer	0.000196	0.00173	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CNR2—pancreatic cancer	0.000191	0.00168	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000191	0.00168	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000188	0.00166	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SCT—pancreatic cancer	0.000187	0.00165	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRLHR—pancreatic cancer	0.000179	0.00157	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCK—pancreatic cancer	0.000178	0.00157	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CNR2—pancreatic cancer	0.000174	0.00153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GLP1R—pancreatic cancer	0.000174	0.00153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCKAR—pancreatic cancer	0.000171	0.0015	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IAPP—pancreatic cancer	0.000169	0.00149	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ZNRF3—pancreatic cancer	0.000168	0.00148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ACVR1B—pancreatic cancer	0.000168	0.00148	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—HRAS—pancreatic cancer	0.000167	0.00147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000163	0.00143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SHH—pancreatic cancer	0.000156	0.00137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IAPP—pancreatic cancer	0.000154	0.00135	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DTX1—pancreatic cancer	0.000152	0.00134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SSTR3—pancreatic cancer	0.000152	0.00134	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SST—pancreatic cancer	0.000149	0.00131	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTHLH—pancreatic cancer	0.000148	0.0013	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTCH1—pancreatic cancer	0.000148	0.0013	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	0.000146	0.00128	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SSTR1—pancreatic cancer	0.000146	0.00128	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPY—pancreatic cancer	0.000143	0.00126	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SSTR2—pancreatic cancer	0.00014	0.00123	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CNR1—pancreatic cancer	0.000137	0.00121	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCKBR—pancreatic cancer	0.000135	0.00119	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SST—pancreatic cancer	0.000135	0.00119	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000135	0.00119	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.000133	0.00117	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GCG—pancreatic cancer	0.000133	0.00117	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—pancreatic cancer	0.00013	0.00114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.000129	0.00114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—DTX4—pancreatic cancer	0.000127	0.00112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GLI1—pancreatic cancer	0.000127	0.00112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000126	0.00111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.000126	0.00111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CNR1—pancreatic cancer	0.000125	0.0011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NRP1—pancreatic cancer	0.000124	0.00109	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000124	0.00109	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GCG—pancreatic cancer	0.00012	0.00106	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HEY2—pancreatic cancer	0.000119	0.00105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GAST—pancreatic cancer	0.000116	0.00103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.000115	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AGTR1—pancreatic cancer	0.000115	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SCT—pancreatic cancer	0.00011	0.000972	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HEY1—pancreatic cancer	0.00011	0.000972	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000107	0.00094	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCK—pancreatic cancer	0.000105	0.000927	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CNR2—pancreatic cancer	0.000103	0.000904	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GLP1R—pancreatic cancer	0.000103	0.000904	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL8—pancreatic cancer	0.000103	0.000903	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCKAR—pancreatic cancer	0.000101	0.000889	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—HRAS—pancreatic cancer	9.94e-05	0.000876	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JAG2—pancreatic cancer	9.79e-05	0.000862	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MEN1—pancreatic cancer	9.64e-05	0.00085	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SHH—pancreatic cancer	9.2e-05	0.00081	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH4—pancreatic cancer	9.14e-05	0.000805	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IAPP—pancreatic cancer	9.09e-05	0.0008	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTHLH—pancreatic cancer	8.72e-05	0.000768	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTCH1—pancreatic cancer	8.72e-05	0.000768	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SST—pancreatic cancer	7.98e-05	0.000703	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—pancreatic cancer	7.87e-05	0.000693	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JAG1—pancreatic cancer	7.81e-05	0.000688	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH3—pancreatic cancer	7.77e-05	0.000685	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CNR1—pancreatic cancer	7.36e-05	0.000648	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—pancreatic cancer	7.14e-05	0.000629	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GCG—pancreatic cancer	7.11e-05	0.000626	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CD—pancreatic cancer	6.92e-05	0.000609	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AGTR1—pancreatic cancer	6.78e-05	0.000597	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STK11—pancreatic cancer	6.68e-05	0.000589	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CD—pancreatic cancer	6.28e-05	0.000553	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.03e-05	0.000531	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SMAD4—pancreatic cancer	5.85e-05	0.000516	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL8—pancreatic cancer	5.79e-05	0.00051	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HES1—pancreatic cancer	5.72e-05	0.000504	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CB—pancreatic cancer	5.47e-05	0.000482	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL8—pancreatic cancer	5.26e-05	0.000463	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TERT—pancreatic cancer	5.01e-05	0.000441	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIF1A—pancreatic cancer	4.79e-05	0.000422	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TSC2—pancreatic cancer	4.78e-05	0.000421	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOE—pancreatic cancer	4.68e-05	0.000412	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KDR—pancreatic cancer	4.58e-05	0.000404	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NFKBIA—pancreatic cancer	4.36e-05	0.000384	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOTCH1—pancreatic cancer	4.32e-05	0.00038	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—pancreatic cancer	4.22e-05	0.000372	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NRAS—pancreatic cancer	4.22e-05	0.000372	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGF—pancreatic cancer	4.17e-05	0.000367	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—pancreatic cancer	3.85e-05	0.000339	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CD—pancreatic cancer	3.71e-05	0.000327	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.68e-05	0.000324	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—pancreatic cancer	3.63e-05	0.00032	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—pancreatic cancer	3.34e-05	0.000294	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CB—pancreatic cancer	3.23e-05	0.000285	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL8—pancreatic cancer	3.11e-05	0.000274	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRAS—pancreatic cancer	3.09e-05	0.000272	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	3e-05	0.000264	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	2.97e-05	0.000262	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	2.9e-05	0.000255	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	2.87e-05	0.000253	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	2.81e-05	0.000248	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	2.79e-05	0.000246	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	2.73e-05	0.00024	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	2.59e-05	0.000228	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	2.52e-05	0.000222	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	2.5e-05	0.00022	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	2.49e-05	0.00022	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	2.32e-05	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	2.32e-05	0.000204	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	2.27e-05	0.0002	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	2.15e-05	0.000189	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.97e-05	0.000174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	1.91e-05	0.000168	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	1.82e-05	0.000161	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	1.61e-05	0.000142	CbGpPWpGaD
